The firm will advance an exosome isolation technology that it says allows for the capture of exosomes more efficiently and sensitively than existing platforms.
The Ann Arbor-based biotech startup will use the funding to develop its microbubble technology that allows for removal of biomolecules from biological samples.
The firm plans to use the funding to expand commercial sales efforts, advance CDx partnerships, build its regulatory infrastructure, and explore new R&D avenues.
Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.
